Incidence of primary hepatitis C virus infection among people who inject drugs in Australia pre- and post- unrestricted availability of direct acting antiviral therapies.

Australia has had a 53% reduction in primary hepatitis C virus (HCV) incidence among people who inject drugs following unrestricted availability of HCV direct acting antiviral therapy in March 2016. Given PWID are the predominant population at risk of HCV infection in Australia, findings add to the evidence that Australia has likely met its 2020 Global Health Sector Strategy sub-target of a 30% decline in new infections.